Targeting non-malignant disorders with tyrosine kinase inhibitors

被引：113

作者：

Grimminger, Friedrich ^{[1
,2
]}

Schermuly, Ralph T. ^{[2
,3
]}

Ghofrani, Hossein A. ^{[1
,2
]}

机构：

[1] Univ Hosp Giessen & Marburg, Med Clin 2 4 5, D-35398 Giessen, Germany

[2] Univ Giessen, Lung Ctr, D-35398 Giessen, Germany

[3] Max Planck Inst Heart & Lung Res, D-61231 Bad Nauheim, Germany

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 12期

关键词：

ENDOTHELIAL GROWTH-FACTOR; PULMONARY ARTERIAL-HYPERTENSION; GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; SMOOTH-MUSCLE-CELLS; FACTOR-RECEPTOR-BETA; ORGAN ALLOGRAFT-REJECTION; PLACEBO-CONTROLLED TRIAL; FOCAL ADHESION KINASE;

D O I：

10.1038/nrd3297

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Receptor and non-receptor tyrosine kinases are involved in multiple proliferative signalling pathways. Imatinib, one of the first tyrosine kinase inhibitors (TKIs) to be approved, revolutionized the treatment of chronic myelogenous leukaemia, and other TKIs with different spectra of kinase inhibition are used to treat renal cell carcinoma, non-small-cell lung cancer and colon cancer. Studies also support the potential use of TKIs as anti-proliferative agents in non-malignant disorders such as cardiac hypertrophy, and in benign-proliferative disorders including pulmonary hypertension, lung fibrosis, rheumatoid disorders, atherosclerosis, in-stent restenosis and glomerulonephritis. In this Review, we provide an overview of the most recent developments-both experimental as well as clinical-regarding the therapeutic potential of TKIs in non-malignant disorders.

引用

页码：956 / 970

页数：15

共 234 条

[1] Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis [J].

Abdollahi, A ;

Li, ML ;

Ping, G ;

Plathow, C ;

Domhan, S ;

Kiessling, F ;

Lee, LB ;

McMahon, G ;

Gröne, HJ ;

Lipson, KE ;

Huber, PE .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (06) :925-935

[2] Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].

Achen, MG ;

Jeltsch, M ;

Kukk, E ;

Mäkinen, T ;

Vitali, A ;

Wilks, AF ;

Alitalo, K ;

Stacker, SA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553

[3] Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice [J].

Aono, Y ;

Nishioka, Y ;

Inayama, M ;

Ugai, M ;

Kishi, J ;

Uehara, H ;

Izumi, K ;

Sone, S .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (11) :1279-1285

[4]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[5] The selectivity of protein kinase inhibitors: a further update [J].

Bain, Jenny ;

Plater, Lorna ;

Elliott, Matt ;

Shpiro, Natalia ;

Hastie, C. James ;

Mclauchlan, Hilary ;

Klevernic, Iva ;

Arthur, J. Simon C. ;

Alessi, Dario R. ;

Cohen, Philip .

BIOCHEMICAL JOURNAL, 2007, 408 :297-315

[6] Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus [J].

Balasubramaniam, V ;

Le Cras, TD ;

Ivy, DD ;

Grover, TR ;

Kinsella, JP ;

Abman, SH .

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 284 (05) :L826-L833

[7] Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries [J].

Banai, S ;

Gertz, SD ;

Gavish, L ;

Chorny, M ;

Perez, LS ;

Lazarovichi, G ;

Ianculuvich, M ;

Hoffmann, M ;

Orlowski, M ;

Golomb, G ;

Levitzki, A .

CARDIOVASCULAR RESEARCH, 2004, 64 (01) :165-171

[8] PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine [J].

Banai, S ;

Wolf, Y ;

Golomb, G ;

Pearle, A ;

Waltenberger, J ;

Fishbein, I ;

Schneider, A ;

Gazit, A ;

Perez, L ;

Huber, R ;

Lazarovichi, G ;

Rabinovich, L ;

Levitzki, A ;

Gertz, SD .

CIRCULATION, 1998, 97 (19) :1960-1969

[9]

Baroni SS, 2006, NEW ENGL J MED, V354, P2667

[10] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

← 1 2 3 4 5 6 7 8 9 10 →